[Efficacy of DACE regimen on relapsed and refractory non-Hodgkin's lymphoma].
OBJECTIVE
There is no standard salvage regimen for patients with relapsed and refractory non-Hodgkin's lymphoma (NHL) at present. This study was to evaluate the efficacy of DACE regimen, as a salvage regimen, on relapsed and refractory NHL, and observe the adverse events.


METHODS
From May 2001 to May 2006, 61 patients with relapsed and refractory NHL received chemotherapy of DACE regimen: intravenous infusion of cisplatin (20 mg/m(2)) on Days 1-5, etoposide (100 mg) on Days 1-5, cytarabine (150 mg) on Days 1-3, and dexamethone (15 mg/m(2)) on Days 1-5; repeated every 3 weeks. The efficacy and adverse events were evaluated according to the World Health Organization criteria.


RESULTS
The overall response rates were 63.9% after two cycles of chemotherapy and 72.1% after four cycles. The median remission time lasted 4.7 months (1-58 months). The 1-year survival rate was 29.5%û the 2-year survival rate was 21.3%. Myelosuppression was the major adverse event: the occurrence rate of grade III-IV myelosuppression was 49.1%û it was well tolerated.


CONCLUSIONS
DACE regimen is an effective salvage regimen in treating patients with relapsed and refractory NHL.
Zhang
Ming-Zhi
MZ
Department of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, 450052, PR China. mingzhi_zhang@126.com
Zang
Wei-Ping
WP
Song
Min
M
Geng
Li
L
Li
Xin
X
Wang
Rui-Lin
RL
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D003561:Cytarabine; D005047:Etoposide; D003907:Dexamethasone; D002945:Cisplatin